The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

This study has been completed.
Sponsor:
Information provided by:
Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:
NCT01283958
First received: January 25, 2011
Last updated: NA
Last verified: May 2010
History: No changes posted

January 25, 2011
January 25, 2011
September 2007
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome
Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

12 patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Eisenmenger's Syndrome
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
May 2010
Not Provided

Inclusion Criteria:

  • patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Exclusion Criteria:

Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01283958
no sponsor
Not Provided
Song I Yang, Gil Hospital, Gachon University of Medicine
Gachon University Gil Medical Center
Not Provided
Not Provided
Gachon University Gil Medical Center
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP